BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20444754)

  • 1. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
    Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
    Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Lunt M; Watson KD; Dixon WG; ; Symmons DP; Hyrich KL;
    Arthritis Rheum; 2010 Nov; 62(11):3145-53. PubMed ID: 20662063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Harrison MJ; Dixon WG; Watson KD; King Y; Groves R; Hyrich KL; Symmons DP; ;
    Ann Rheum Dis; 2009 Feb; 68(2):209-15. PubMed ID: 18385277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register.
    Rudi T; Zietemann V; Meissner Y; Zink A; Krause A; Lorenz HM; Kneitz C; Schaefer M; Strangfeld A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Hyrich KL; ; Silman AJ; Symmons DP;
    Arthritis Rheum; 2007 Sep; 56(9):2905-12. PubMed ID: 17763428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
    Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
    Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study.
    Kelly CA; Nisar M; Arthanari S; Carty S; Woodhead FA; Price-Forbes A; Middleton D; Dempsey O; Miller D; Basu N; Dawson J; Sathi N; Ahmad Y; Palmer E; Iqbal K; Janakiraman G; Koduri G; Young A
    Rheumatology (Oxford); 2021 Apr; 60(4):1882-1890. PubMed ID: 33150434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP;
    Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Davies R; Galloway JB; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Oct; 70(10):1831-4. PubMed ID: 21784722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Soliman MM; Ashcroft DM; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2011 Apr; 70(4):583-9. PubMed ID: 21330639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.
    Mena-Vázquez N; Godoy-Navarrete FJ; Manrique-Arija S; Aguilar-Hurtado MC; Romero-Barco CM; Ureña-Garnica I; Espildora F; Añón-Oñate I; Pérez-Albaladejo L; Gomez-Cano C; Jimenez-Núñez FG; Padin-Martín MI; Fernández-Nebro A
    Clin Rheumatol; 2021 Jan; 40(1):133-142. PubMed ID: 32557255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
    Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
    Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients.
    Sparks JA; Jin Y; Cho SK; Vine S; Desai R; Doyle TJ; Kim SC
    Rheumatology (Oxford); 2021 Aug; 60(8):3689-3698. PubMed ID: 33462611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).
    Dixon WG; Hyrich KL; Watson KD; Lunt M; Galloway J; Ustianowski A; ; Symmons DP;
    Ann Rheum Dis; 2010 Mar; 69(3):522-8. PubMed ID: 19854715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register.
    Mercer LK; Green AC; Galloway JB; Davies R; Lunt M; Dixon WG; Watson KD; ; Symmons DP; Hyrich KL;
    Ann Rheum Dis; 2012 Jun; 71(6):869-74. PubMed ID: 22241900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
    Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
    BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.